Kathryn Romano Sells 12,500 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the sale, the chief accounting officer owned 19,318 shares in the company, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Krystal Biotech Stock Down 0.9%

Shares of Krystal Biotech stock opened at $270.26 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $295.98. The business’s fifty day moving average is $261.21 and its two-hundred day moving average is $204.49. The firm has a market cap of $7.84 billion, a PE ratio of 40.52 and a beta of 0.49.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC grew its position in Krystal Biotech by 4.4% in the third quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after acquiring an additional 117,777 shares in the last quarter. State Street Corp lifted its stake in shares of Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after acquiring an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. raised its position in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares in the last quarter. Braidwell LP grew its position in shares of Krystal Biotech by 81.6% during the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after buying an additional 327,067 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock worth $85,174,000 after buying an additional 7,194 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KRYS has been the topic of several recent analyst reports. The Goldman Sachs Group increased their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Citigroup upped their price target on shares of Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Chardan Capital increased their target price on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Bank of America lifted their target price on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Finally, TD Cowen restated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $277.89.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.